The company has developed several proprietary immuno-oncology therapeutic platforms, including TriTETM, CCNKTM, and CCMφTM. The pipeline antibodies developed based on these platforms could stimulate or modulate immune cells to fight against cancer.
CytoCares is a pioneer in utilizing of “Two-Signal” system of T cell activation in the multi-specific antibody design and has expanded its expertise from hematologic malignancies to solid tumor.
Trispecific T-cell Engager (TriTE) offering full activation signal to T cell through co-engagement of TCR/CD3 and co-stimulatory receptor
NK activation receptor agonists or inhibitory receptor antagonists for effective tumor killing
Marcrophage revitalize agents to enhance innate as well as adaptive immunity for cancer treatment
惠和生物凭借2023年度在生物医药创新领域的积极创新研究成果和临床研究表现,跻身浦东新区2023年度创新创业20强行列,荣获“2023年度浦东新区创新创业奖”。本次获奖是对惠和生物扎根浦东、多年深耕和坚持本土原创创新的又一次认可与鼓励。惠和生物首席运营官曾立博士受邀出席表彰活动并代表惠和生物领取荣誉奖项。
由复旦生科全球校友会、基因技术教育部工程研究中心、复旦大学校友会光华生命健康分会主办,苏州近岸蛋白质科技股份有限公司承办的复旦大学生命健康行业生态协作沙龙在苏州金鸡湖畔顺利举行。惠和生物首席运营官曾立博士受邀参加了此次沙龙,共同探讨学习生物医药行业在价值重构的新局面下如何创新突破,加强协作,挖掘细分赛道的发展机遇,共建生物医药创新协作新生态。
惠和生物凭借项目“生物药版“CAR-T”分子CC312的研究与开发”在上海市产业技术大会上荣获“2023全球未来产业之星大赛”项目组风云奖。